🇺🇸 FDA
Pipeline program

ACR-368

ACR-368-201 (GOG 3082)

Phase 2 small_molecule active

Quick answer

ACR-368 for Endometrial Adenocarcinoma is a Phase 2 program (small_molecule) at Acrivon Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Acrivon Therapeutics
Indication
Endometrial Adenocarcinoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials